The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clinicoecon Outcomes Res
Главные авторы: Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2015
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://ncbi.nlm.nih.gov/pubmed/26719716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S87261
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы